Sodium-glucose co-transporter 2 inhibitors and hematopoiesis.
J Cell Physiol
; 237(10): 3778-3787, 2022 10.
Article
en En
| MEDLINE
| ID: mdl-35951776
ABSTRACT
Many patients with diabetes mellitus, especially those with chronic kidney disorders, have some degree of anemia due to a spectrum of causes and underlying pathophysiologic pathways. As such, enhancement in erythropoiesis is important in these patients. Sodium-glucose cotransporter 2 inhibitors (SGLT2i) are a relatively new class of antidiabetic drugs with confirmed protective effects in kidney and cardiovascular tissues. Recent evidence suggests that these drugs may provide additional benefits in enhancing hematopoietic processes in diabetic patients. Though the exact mediating pathways have not been fully elucidated, cellular mechanisms are likely involved. In the current study, we present the potential pathways by which SGLT2i may modulate hematopoiesis and stimulate erythropoiesis.
Palabras clave
Texto completo:
1
Banco de datos:
MEDLINE
Asunto principal:
Simportadores
/
Diabetes Mellitus Tipo 2
/
Inhibidores del Cotransportador de Sodio-Glucosa 2
Límite:
Humans
Idioma:
En
Año:
2022
Tipo del documento:
Article